NYXH logo

NYXOAH SA

NYXHNASDAQ
πŸ† #3952 by market capEarnings Mar 17 Β· PostUS Equity
β€”β€”
Quote unavailable
πŸ””
Track NYXH
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$82M
Small Cap
πŸ“ˆRevenue Growth (YoY)
121.6%
High Growth
πŸ“ŠGross Margin
54.3%
Healthy
πŸ’΅FCF Margin
-250.6%
Thin
βš–οΈP/S Ratio
2.5x
Cheap
Otter Score
β€”
Insufficient data
No chart data available for NYXH.

Trading Snapshot

Day Range
β€”
52-Week Range
$0.80 – $5.39
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
101.8M
Next Earnings
2027-03-17

Fundamentals Snapshot

Annual Revenue
$10M
Last Q Revenue
$9M
P/E Ratio
-0.4
P/S Ratio
2.5x
EPS (TTM)
$-0.92
Dividend Yield
0.00%
Dilution (1yr)
+8.3%
NYXH logo

NYXOAH SA

NYXH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$10Mβ–² +121.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
63.1%β–Ό βˆ’3.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$83Mβ–² +41.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$68Mβ–² +23.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
40.1Mβ–² +8.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$10Mβ–Ό βˆ’$22M YoY
StockOtter Β· stockotter.space

About NYXOAH SA

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
13 analysts
Strong Buy4
Buy6
Hold3
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.